PSTV Stock Forecast & Price Target

Plus Therapeutics is a promising company with a strong pipeline of potential products targeting recurrent glioblastoma and leptomeningeal metastases, both of which are difficult-to-treat cancers with limited treatment options. The company has received significant grants and moved to the next phase of clinical trials for its lead drug, REYOBIQ, which is being evaluated in a NIH/NCI-supported Phase 2 clinical trial in the U.S. The recent Q4 results showed promising revenue and EPS figures, and the company's focus on RNL highlights its commitment to oncology research. The completion of a clinical study and the start of enrollment for a multi-dose trial, along with favorable pharmacoeconomic data for CNSide, signal potential for commercial success and reimbursement. While the recent reverse stock split may cause some market strain, the company's strong fundamentals and promising developments make it an attractive investment opportunity.

Plus Therapeutics is a clinical-stage pharmaceutical company that has made solid progress in its clinical trials and CNSide ramping, potentially driving stock positivity. However, the company is still facing risks, such as failure to demonstrate safety and efficacy in clinical trials, which could impact its attainment of our share price target of $65, based on its current share price and significant potential upside from its NPV analysis. It is important to note that the company has secured major contracts with influential healthcare companies and has favorable feedback from the FDA, but with the recent reverse stock split, it may be wise to wait and see how the company performs before considering investment.